Biotia Raises $9M to Close the Diagnostic Gap for Recurrent and Culture-Negative UTIs

Biotia Raises $9M to Close the Diagnostic Gap for Recurrent and Culture-Negative UTIs

UTIs drive roughly 10.5M office visits and 3M emergency department encounters in the US each year, and the standard workup starts with a urine culture. That culture detects only the fast-growing bacteria, so patients with recurrent infections, catheters, or negative results despite ongoing symptoms often cycle through repeat visits and rounds of antibiotics that fuel drug resistance. Biotia, a diagnostics company spun out of Cornell Tech, target…